Sjögren’s syndrome – diagnosis and contemporary therapeutic possibilities Review article
Article Sidebar
Main Article Content
Abstract
Dry eye syndrome is a group of medical conditions that can be caused by many factors, as a result of which there is an abnormality in moisturizing of the eye surface by a tear film. One of the causes of this disorder is Sjögren’s syndrome, which is an autoimmune disease in which the body produces antibodies against its own proteins. The glands of external secretion, mainly lacrimal and salivary glands are damaged as a result of inflammation. Associated with this side effects, affect negatively and reduce the quality of life, which is why in the following article we present the available therapeutic options for patients suffering from ophthalmological manifestations of Sjögren’s syndrome.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Fuglewicz A, Pękala Ł. Wtórny zespół Sjögrena u chorych z układowymi chorobami tkanki łącznej. Adv Clin Exp Med. 2003; 12(3): 329-39.
3. Akpek EK, Bunya VY, Saldanha IJ. Sjögren’s Syndrome: More Than Just Dry Eye. Cornea. 2019; 38(5): 658-61. http://doi.org/10.1097/ICO.0000000000001865.
4. Kruk K, Rzepakowska A, Osuch-Wójcikiewicz E et al. Zespół Sjögrena – przegląd najnowszych wytycznych diagnostycznych istotnych w praktyce otolaryngologa. Pol Otorhino Rev. 2019: 8(2): 1-6.
5. Zimmermann-Górska I, Grzegorz Goncerz G. Zespół Sjögrena (access: 3.11.2022).
6. Portal Medycyna Praktyczna. Skala oksfordzka (access: 5.12.2022).
7. Akpek EK, Klimava A, Thorne JE et al. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea. 2009; 28: 493-7.
8. Akpek EK, Mathews P, Hahn S et al. Ocular and systemic morbidity in a longitudinal cohort of Sjogren’s syndrome. Ophthalmology. 2015; 122: 56-61.
9. Pieczyński J, Kuklo P. Cyklosporyna A w leczeniu zespołu suchego oka. OphthaTherapy. 2018; 18(2): 85-9. http://doi.org/10.24292/01.OT.290618.04.
10. Meyer K. Chemical structure of hyaluronic acid. Fed Proc. 1958; 17: 1075-7.
11. Shimmura S, Ono M, Shinozaki K et al. Hialuronian sodu Krople do oczu w leczeniu suchego oka. Fr J Oftalmol. 1995; 79: 1007-11. http://doi.org/10.1136/bjo.79.11.007.
12. Yang YJ, Lee WY, Kim YJ et al. A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. Int J Environ Res Public Health. 2021; 18(5): 2383. http://doi.org/10.3390/ijerph18052383.
13. Tsubota K, Goto E, Fujita H et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol. 1999; 83(4): 390-5. http://doi.org/10.1136/bjo.83.4.390.
14. Bowling E, Russell GE. Topical Steroids and the Treatment of Dry Eye (access: 21.11.2022).
15. Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006; 7(8): 675-8. http://doi.org/10.1631/jzus.2006.B0675.
16. de Paiva CS, Pflugfelder SC, Ng SM et al. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019; 9: CD010051. http://doi.org/10.1002/14651858.CD010051.pub2.
17. Johnsen SJ, Brun JG, Gøransson LG et al. Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: A population-based study. Arthritis Care Res. 2013; 65: 816-21.
18. Grigoriadou S, Chowdhury F, Pontarini E et al. Review. B-cell depletion with rituximab in the treatment of primary Sjögren’s syndrome: what have we learnt? Clin Exp Rheumatol. 2019; 37(suppl 118): S217-S224.
19. Safavi F, Rostami A. Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases. Exp Mol Path. 2012; 93: 428-33.
20. Joossen C, Baán A, Moreno-Cinos C et al. A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. Sci Rep. 2020; 10: 17268.